However, recent clinical reports on the use of intravitreal anti-VEGF injections for ROP suggested that these anti-VEGF agents can subsequently escape from the eye into the systemic circulation [9–11], and thus potential adverse systemic effects after such injections should be considered. Here, VEGFA is linked to retinopathy of prematurity.